Application of SUPAC-MR in Processing Postapproval Changes to Modified Release Sold Oral Dosage Forms |
Sah, Hong-Kee
(College of Pharmacy, Catholic University of Daegu)
Cho, Mi-Hyun (College of Pharmacy, Catholic University of Daegu) Park, Sang-Ae (Korea Food & Drug Administration) Yun, Mi-Ok (Korea Food & Drug Administration) Kang, Shin-Jung (Korea Food & Drug Administration) |
1 | FDA, Center for Drug Evaluation and Research, Guidance for Industry - SUPAC-MR: Modified release solid oral dosage forms; Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing and in vivo bioequivalence documentation, September 1997 |
2 | FDA, Center for Drug Evaluation and Research, Guidance for dissolution testing of immediate release solid oral products, August 1997 |
3 | FDA, Center for Drug Evaluation and Research, Oral extended (controlled) release dosage forms: In vivo bioequivalence and in vitro dissolution testing, September 1993 |
4 | FDA, Center for Drug Evaluadon and Research, Guidance for Industry: SUPAC-IR/MR: Immediate release and modified release solid oral dosage forms; Manufacturing equipment addendum, January 1999 |
5 | FDA, Center for Drug Evaluadon and Research, Guidance for Industry: Changes to an approved NDA or ANDA, November 1999 |
6 | FDA, Center for Drug Evaluation and Research, Guidance for Industry - Immediate release solid oral dosage forms; Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995 |
7 | ICH Guideline, Q1C: Stability testing for new dosage forms, November 1996 |
8 | H. Sah, S.A. Park, M.O. Yun and S.J. Kang, Scrutiny made to SUPAC-IR dealing with postapproval changes in immediate release solid oral dosage forms, J. Kor. Pharm. Sci., 34, 57-71 (2004) |
9 | M.J. Rathbone, J. Hadgraft and M.S. Roberts (Eds.), Modifled-Release Drug Delivery Technology, Marcel Dekker Inc, New York, NY, USA, pp. 1-996 (2003) |
10 | FDA, Center for Drug Evaluation and Research, Guidance for Industry - Q1A(R2): Stability testing of new drug substances and products, November 2003 |
11 | ICH Guideline, Q1D: Bracketing and matrixing designs for stability testing of drug substances and drug products, Febmary 2002 |
12 | ICH Guideline, Q1E: Evaluation of stability data, February 2003 |
13 | FDA, Guidance for Industry - Extended release oral dosage forms: Development, evaluation and application of in vitrol in vivo correlations, September 1997 |
14 | FDA, Center for Drug Evaluadon and Research, Guidance for Industry: Changes to an approved NDA or ANDA(revision 1), April 2004 |
15 | 식품의약품안전청 고시 제 2002-62호 '생물학적동등성시험기준' 제 3조 제 4항 |
16 | European Commission, Note to Applicants: Procedures for marketing authorisation - Chapter 5. Variations, February 2004 |
17 | 일본국립의약품식품위생연구소(National Institute of Health Sciences), Division of Drugs, Guideline for bioequivalence studies for formulation changes of oral solid forms, February 2000 |
18 | European Commission, Note to Applicants: Guideline on dossier requirements for type IA and type IB notifications, July 2003 |